Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.
about
Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting AntiviralsExploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3Erythropoietin and hepatitis C therapy: useful adjuvant therapy but remember to treat the patient and not just a numberOutcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal CanadiansNon-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C.The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.Hepatitis C treatment completion rates in routine clinical care.Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS.Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.Capacity enhancement of hepatitis C virus treatment through integrated, community-based care.Stigma in the context of hepatitis C: concept analysis.Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysisResponse-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects.Revolution in hepatitis C antiviral therapy.Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents.Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients.Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients."12 weeks' stopping rule" in the treatment of genotype 1 chronic hepatitis C: two prognostic categories under the same label?Optimal treatment duration for patients with HCV genotype 1 infection.Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
P2860
Q26747561-89EB172C-53AB-4117-9D96-EF922B0B5D34Q27485351-1B739A9E-1677-472C-9690-A0660FDF616EQ27488244-BFCC14C0-469F-40DC-BEEB-4EEF65A6D050Q27488260-EBA6F50E-B7BA-4046-A539-59B6E409F268Q33421239-86D158BF-02EB-42DD-987C-9FEFB50F886FQ34511200-B35E6CF1-D630-4C36-9F90-80AEC26327EDQ34996746-BE26EAAA-8D36-47C7-A5E3-2C11A045C9DDQ35093134-66B5E17E-29BD-432E-AE91-0C856DF099E9Q35769129-2B791EEE-4D0D-4274-81FD-1EDBD99166EEQ36935025-2C60E934-9C8C-45EE-BFD6-3D45DC2F8E40Q37016316-E64AC383-9B43-4D5D-94B1-61366BA958BFQ37136533-DA506E54-A0E8-42CB-9B5F-411C33239D49Q37173294-6908E0C7-A20B-4BF1-85F9-D0DE486B1FDCQ37735902-E30E43A0-CCAF-4FC4-943B-3F48169E4E2AQ38213847-9B2CB83B-EEF5-4671-961D-9D98898EA21CQ38355069-354F5739-2D80-4BCF-BD07-9C0930B8D876Q38530211-25CDF20D-2DFB-41D7-93E8-DD9243B43A5FQ38814211-FBC31AED-F659-4A10-8783-789B6CADDA69Q39913723-A7C74598-FBC4-4BF1-B505-5B67B3445E57Q40142985-02C60EDF-DCC9-4548-BB34-A50027237FF1Q42983924-21216B4F-7CAB-46D0-9F2B-8A220803F677Q43046842-DF893EA1-779E-4D9C-8EDB-67352FDA60BCQ45836877-43271C5E-5BC9-4536-9D26-6AD7ECEAC3EDQ46866205-E69DD5CF-A815-46A0-AEE7-EC69F706258FQ55717379-3CF49B12-E200-4DE2-8FBC-2F6961357971
P2860
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Treating chronic hepatitis C w ...... ibavirin in clinical practice.
@en
Treating chronic hepatitis C with pegylated interferon alfa-2a
@nl
type
label
Treating chronic hepatitis C w ...... ibavirin in clinical practice.
@en
Treating chronic hepatitis C with pegylated interferon alfa-2a
@nl
prefLabel
Treating chronic hepatitis C w ...... ibavirin in clinical practice.
@en
Treating chronic hepatitis C with pegylated interferon alfa-2a
@nl
P2093
P2860
P1476
Treating chronic hepatitis C w ...... ibavirin in clinical practice.
@en
P2093
CANADIAN PEGASYS STUDY GROUP
E M Yoshida
J Heathcote
M Deschenes
R J Bailey
P2860
P304
P356
10.1111/J.1365-2036.2006.02748.X
P407
P577
2006-02-01T00:00:00Z